These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Lamoth F; Alexander BD Antimicrob Agents Chemother; 2015 Jul; 59(7):4308-11. PubMed ID: 25896696 [TBL] [Abstract][Full Text] [Related]
13. Stress-Induced Changes in the Lipid Microenvironment of β-(1,3)-d-Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus. Satish S; Jiménez-Ortigosa C; Zhao Y; Lee MH; Dolgov E; Krüger T; Park S; Denning DW; Kniemeyer O; Brakhage AA; Perlin DS mBio; 2019 Jun; 10(3):. PubMed ID: 31164462 [No Abstract] [Full Text] [Related]
14. Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus. Wring S; Murphy G; Atiee G; Corr C; Hyman M; Willett M; Angulo D Clin Pharmacol Drug Dev; 2019 Jan; 8(1):60-69. PubMed ID: 29947477 [TBL] [Abstract][Full Text] [Related]
15. Role of FKS Gene in the Susceptibility of Pathogenic Fungi to Echinocandins. Hori Y; Shibuya K Med Mycol J; 2018; 59(2):E31-E40. PubMed ID: 29848909 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis. Ghannoum M; Long L; Larkin EL; Isham N; Sherif R; Borroto-Esoda K; Barat S; Angulo D Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610204 [TBL] [Abstract][Full Text] [Related]
17. A comparative evaluation of properties and clinical efficacy of the echinocandins. Kim R; Khachikian D; Reboli AC Expert Opin Pharmacother; 2007 Jul; 8(10):1479-92. PubMed ID: 17661730 [TBL] [Abstract][Full Text] [Related]
18. Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species. Schell WA; Jones AM; Borroto-Esoda K; Alexander BD Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827419 [TBL] [Abstract][Full Text] [Related]
19. A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis. Larkin EL; Long L; Isham N; Borroto-Esoda K; Barat S; Angulo D; Wring S; Ghannoum M Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30885896 [TBL] [Abstract][Full Text] [Related]
20. Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Gamal A; Chu S; McCormick TS; Borroto-Esoda K; Angulo D; Ghannoum MA Front Cell Infect Microbiol; 2021; 11():642358. PubMed ID: 33791244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]